(126 days)
The iPRIMETM Viscodelivery System is a manually operated device for delivery of small amounts of viscoelastic fluid, for example HEALON® PRO from Johnson & Johnson Vision, Amvisc@ from Bausch & Lomb, or PROVISC® from Alcon, during ophthalmic surgery.
The iPRIMET™ Viscodelivery System is a sterile, single-use ophthalmic surgical instrument for dispensing cohesive viscoelastic fluid (supplied separately, at point of use) during ophthalmic surgery. The iPRIMET™ Viscodelivery System is a delivery device for delivering viscoelastic fluid. The procedure is performed by a trained ophthalmic professional in a sterile surgical setting. The iPRIME device is filled by the user, at the point of use, with FDA approved commercially available cohesive viscoelastic fluid (e.g. HEALON® PRO, Amvisc® or PROVISC®; sold and supplied separately). The iPRIME device consists of a handpiece which includes a reservoir, dispense trigger, cannula, slide button, rotatable hub, and microcatheter manufactured from medical grade materials. The slide button allows the user to adjust the microcatheter length. The dispense trigger dispenses the viscoelastic fluid. The rotatable hub allows the user to adjust the angle of the cannula in order to dispense viscoelastic fluid into other areas within the anterior chamber. The iPRIMET™ Viscodelivery System serves as dispensary means to deliver cohesive viscoelastic fluid. The OVD device containing the viscoelastic fluid is connected to the iPRIME luer fitting and viscoelastic is pumped into the iPRIME device. After the device is fully primed and the microcatheter has been extended to the desired location, the user advances forward the dispense trigger delivering a small amount of viscoelastic fluid into the desired location within the anterior chamber of the eye.
The iPRIME™ Viscodelivery System was subjected to various non-clinical tests to demonstrate its performance and substantial equivalence to the predicate device.
1. Table of Acceptance Criteria and Reported Device Performance
| Test Category | Specific Test | Acceptance Criteria | Reported Device Performance |
|---|---|---|---|
| Functional & Performance | Joint Strength Testing | Able to perform according to intended use and predicate device characteristics | Met all acceptance criteria and performs as intended |
| Microcatheter and Cannula Extension/Retraction | Able to perform according to intended use and predicate device characteristics | Met all acceptance criteria and performs as intended | |
| Priming/Dispense Volume Testing | Able to perform according to intended use and predicate device characteristics | Met all acceptance criteria and performs as intended | |
| Corrosion Testing | Able to perform according to intended use and predicate device characteristics | Met all acceptance criteria and performs as intended | |
| Human Factors Engineering Evaluation | Able to perform according to intended use and predicate device characteristics | Met all acceptance criteria and performs as intended | |
| Biocompatibility | Cytotoxicity (ISO 10993-1: 2018) | Components contacting directly or indirectly with patient are biocompatible | Demonstrated biocompatibility |
| Sensitization (ISO 10993-1: 2018) | Components contacting directly or indirectly with patient are biocompatible | Demonstrated biocompatibility | |
| Intracutaneous Irritation (ISO 10993-1: 2018) | Components contacting directly or indirectly with patient are biocompatable | Demonstrated biocompatibility | |
| Systemic Toxicity (ISO 10993-1: 2018) | Components contacting directly or indirectly with patient are biocompatible | Demonstrated biocompatibility | |
| Package Integrity | Packaging Visual Inspection | Sterile barrier maintained throughout the three-month shelf life | Maintained sterile barrier |
| Packaging Peel Test | Sterile barrier maintained throughout the three-month shelf life | Maintained sterile barrier | |
| Packaging Bubble Test | Sterile barrier maintained throughout the three-month shelf life | Maintained sterile barrier | |
| Dispensed Volume | Viscoelastic Fluid (per activation) | 2.7 µL of cohesive viscoelastic fluid per activation of dispense trigger | 2.7 µL per activation (No total volume limit specified for the proposed device) |
2. Sample Size Used for the Test Set and Data Provenance
The provided document does not specify the exact sample sizes for each non-clinical test. It only states that the device was "subjected to the following functional and performance tests." The data provenance is from non-clinical testing performed on the iPRIME™ Viscodelivery System by the manufacturer, Glaukos Corporation. This is not patient data, so concepts like country of origin or retrospective/prospective do not apply in the same way.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
Not applicable. The ground truth for these non-clinical tests is based on objective measurements and established engineering and biological standards, not expert clinical interpretation.
4. Adjudication Method for the Test Set
Not applicable. The non-clinical tests involve objective measurements against predefined acceptance criteria, rather than subjective interpretation requiring adjudication.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No. The document explicitly states: "Clinical data are not included in this submission and are not required. Substantial equivalence is based on technological comparison." Therefore, no MRMC comparative effectiveness study was performed.
6. Standalone (Algorithm Only) Performance Study
Not applicable. The iPRIME™ Viscodelivery System is a medical device, not an algorithm or AI software. Its performance is evaluated through non-clinical functional, performance, and biocompatibility testing.
7. Type of Ground Truth Used
The ground truth for the non-clinical tests used objective measurements and adherence to established standards and criteria for device functionality, material biocompatibility (ISO 10993-1: 2018), and package integrity. For the dispensed volume, the ground truth is the measured volume of viscoelastic fluid dispensed per activation.
8. Sample Size for the Training Set
Not applicable. This is a physical medical device, not a software algorithm, so there is no "training set" in the context of machine learning.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no training set for this device.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
January 06, 2022
Glaukos Corporation Alex Bhaskarla Senior Regulatory Affairs Associate 229 Avenida Fabricante San Clemente, CA 92672
Re: K212797
Trade/Device Name: iPrime Viscodelivery System Regulation Number: 21 CFR 880.5725 Regulation Name: Infusion Pump Regulatory Class: Class II Product Code: MRH Dated: August 31, 2021 Received: September 2, 2021
Dear Alex Bhaskarla:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803)
{1}------------------------------------------------
for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
for Tieuvi Nguven, Ph.D. Director DHT1A: Division of Ophthalmic Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K212797
Device Name iPRIME™M Viscodelivery System
Indications for Use (Describe)
The iPRIMETM Viscodelivery System is a manually operated device for delivery of small amounts of viscoelastic fluid, for example HEALON® PRO from Johnson & Johnson Vision, Amvisc@ from Bausch & Lomb, or PROVISC® from Alcon, during ophthalmic surgery.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (6/20)
Page 1 of 1
PSC Publishing Services (301) 443-6740 EF
GLAUKOS CORPORATION RESPONSE FOR iPRIME™ VISCODELIVERY SYSTEM 510(K) - K212797
CONFIDENTIAL VOLUME I OF III, PAGE 33
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.
{3}------------------------------------------------
510k Summary
| 510(k) Owner: | Glaukos Corporation229 Avenida FabricanteSan Clemente, California 92672Telephone: 949-367-9600Fax: 949-367-9984 |
|---|---|
| Contact Person: | Alex BhaskarlaSenior Regulatory Affairs AssociateTelephone: 949-481-0672Fax: 949-367-9984 |
| Date Prepared: | November 19, 2021 |
| Device TradeName: | iPRIME™ Viscodelivery System |
| Classification: | II |
| ClassificationName: | Infusion Pump |
| Product Code: | MRH |
| RegulationNumber: | CFR 880.5725 |
| Predicate Device: | Sight Sciences VISCO360™ Viscosurgical System (K171905) |
{4}------------------------------------------------
| Device Description: | The iPRIMET™ Viscodelivery System is a sterile, single-use ophthalmic surgical instrument for dispensing cohesive viscoelastic fluid (supplied separately, at point of use) during ophthalmic surgery. The iPRIMET™ Viscodelivery System is a delivery device for delivering viscoelastic fluid. The procedure is performed by a trained ophthalmic professional in a sterile surgical setting. The iPRIME device is filled by the user, at the point of use, with FDA approved commercially available cohesive viscoelastic fluid (e.g. HEALON® PRO, Amvisc® or PROVISC®; sold and supplied separately). The iPRIME device consists of a handpiece which includes a reservoir, dispense trigger, cannula, slide button, rotatable hub, and microcatheter manufactured from medical grade materials. The slide button allows the user to adjust the microcatheter length. The dispense trigger dispenses the viscoelastic fluid. The rotatable hub allows the user to adjust the angle of the cannula in order to dispense viscoelastic fluid into other areas within the anterior chamber. The iPRIMET™ Viscodelivery System serves as dispensary means to deliver cohesive viscoelastic fluid. The OVD device containing the viscoelastic fluid is connected to the iPRIME luer fitting and viscoelastic is pumped into the iPRIME device. After the device is fully primed and the microcatheter has been extended to the desired location, the user advances forward the dispense trigger delivering a small amount of viscoelastic fluid into the desired location within the anterior chamber of the eye. |
|---|---|
| Indication for Use: | The iPRIMET™ Viscodelivery System is a manually operated device for delivery of small amounts of viscoelastic fluid, for example HEALON® PRO from Johnson & Johnson Vision, Amvisc® from Bausch & Lomb, or PROVISC® from Alcon, during ophthalmic surgery. |
{5}------------------------------------------------
Comparison of Technological Characteristics with the Predicate Device
The technical characteristics of the iPRIME™ Viscodelivery System are substantially equivalent to the predicate device VISCO™ 360 Viscosurgical System (K171905). The iPRIME™ Viscodelivery System and predicate device are manually operated devices for the controlled delivery of small amounts of viscoelastic fluid and dispenses these fluids based on the principle of exchanging volumes much like a syringe. Table 1 below compares the attributes of the iPRIME™ Viscodelivery System with the predicate device. The iPRIME™ Viscodelivery System is substantially equivalent to the predicate device as indicated below:
| TABLE 1. SUBJECT AND PREDICATE DEVICE COMPARISON SUMMARY | ||
|---|---|---|
| Features | Proposed DeviceiPRIMETM Viscodelivery System | Predicate DeviceVISCOTM360 Viscosurgical System (K171905) |
| Intended Use | User manually operated handheld device for delivery of viscoelastic fluid during ophthalmic surgery | Same |
| Indications for Use | The iPRIMETM Viscodelivery System is a manually operated device for delivery of small amounts of viscoelastic fluid, for example HEALON® PRO from Johnson & Johnson Vision, Amvisc® from Bausch & Lomb, or PROVISC® from Alcon, during ophthalmic surgery. | The Sight Sciences VISCOTM360 Viscosurgical System is a manually operated device for delivery of small amounts of viscoelastic fluid, for example HealonTM or HealonGVTM from Abbot Medical Optics (AMO), AmviscTM from Bausch & Lomb, or PROVISCTM from Alcon, during ophthalmic surgery. |
| DeviceClassificationProduct Code | Class IIMRH | Same |
| DispensingDesign | Passive volume dispensing syringe mechanism | Same |
| DispensingControl | Manual forward slide of trigger to dispense viscoelastic fluid | Manual rotation of actuator wheel to dispense viscoelastic fluid |
| Materials | Medical grade stainless steel cannula and ABS molded plastic components | Same |
| MicrocatheterDimensions | Microcatheter (17mm max L, 200 microns OD | Microcatheter (21 mm L, 200 microns OD |
| ViscoelasticFluid | 2.7 µL of cohesive viscoelastic fluid (supplied separately) per activation of dispense trigger. No total volume limit | 4.5 µL per delivery, 9 µL total volume dispensed |
| TargetAnatomy | Anterior chamber of eye | Same |
{6}------------------------------------------------
| Summary of Non-clinicalData: | The iPRIMETM Viscodelivery System was subjected tobiocompatibility, sterilization, package integrity, andperformance tests to ensure its functionality is consistent withcohesive viscoelastic fluid infusion pumps. |
|---|---|
| The iPRIME device was subjected to the following functionaland performance tests to ensure its stability over a three-monthshelf life: | |
| Joint strength testing Microcatheter and cannula extension/retraction testing Priming/dispense volume testing Corrosion testing Human factors engineering evaluation | |
| Biocompatibility testing was performed in accordance with ISO10993-1: 2018 to ensure the direct and indirect patient contactingcomponents are biocompatible: | |
| Cytotoxicity Sensitization Intracutaneous irritation Systemic toxicity | |
| Package integrity testing was performed in order to ensure thesterile barrier is maintained throughout the three-month shelflife: | |
| Packaging visual inspection Packaging peel test Packaging bubble test | |
| Acceptance criteria for testing was based on the ability toperform according to the intended use and predicate devicecharacteristics. The tests results show that the iPRIMETMViscodelivery System met all acceptance criteria and performsas intended. | |
| Summary of ClinicalData: | Clinical data are not included in this submission and are notrequired. Substantial equivalence is based on technologicalcomparison. |
| Conclusion from Data: | The iPRIMET™ Viscodelivery System meets all product designrequirements and applicable standards. The iPRIMETMViscodelivery System has been shown to be substantiallyequivalent to the predicate device. |
§ 880.5725 Infusion pump.
(a)
Identification. An infusion pump is a device used in a health care facility to pump fluids into a patient in a controlled manner. The device may use a piston pump, a roller pump, or a peristaltic pump and may be powered electrically or mechanically. The device may also operate using a constant force to propel the fluid through a narrow tube which determines the flow rate. The device may include means to detect a fault condition, such as air in, or blockage of, the infusion line and to activate an alarm.(b)
Classification. Class II (performance standards).